STOCK TITAN
  1. Home
  2. Sec-filings
  3. VRXA
  4. [6-K] Veraxa Biotech Holding AG Current Report (Foreign Issuer)

Veraxa Biotech (NASDAQ: VRXA) unveils new cancer platform data at BIO 2026

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Veraxa Biotech AG reported new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform for more precise, tumor-restricted cancer treatment. In studies, BiTAC-ADCs discriminated between breast cancer and healthy cells and showed efficient, dose-dependent killing of 3D tumor cell spheroids.

The platform uses two complementary antibody-delivered precursors to keep payloads inactive in circulation and activate them only inside tumor cells, aiming to reduce off-tumor toxicity. Veraxa will attend the BIO International Convention in San Diego from June 22-25, 2026 to discuss partnering opportunities for its BiTAC-ADC and BiTAC-TCE platforms.

Positive

  • None.

Negative

  • None.
Press release date June 18, 2026 Date of BiTAC-ADC proof-of-concept announcement
BIO International Convention dates June 22-25, 2026 San Diego partnering meetings for BiTAC-ADC and BiTAC-TCE
Location San Diego, California BIO International Convention 2026 venue
Cancer model Breast cancer cells BiTAC-ADCs discriminated between cancer and healthy cells in vitro
3D model type 3D tumor cell spheroids BiTAC-ADCs showed efficient, dose-dependent killing in vitro
BiTAC-ADC medical
"in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform"
An antibody-drug conjugate (ADC) with the investigational name BITAC-ADC is a targeted cancer therapy that combines a cancer-seeking antibody with a potent drug, so the treatment behaves like a guided missile that delivers chemotherapy directly to tumor cells while sparing healthy tissue. Investors watch ADC candidates closely because their clinical trial results, safety profile and regulatory approvals can drastically affect a developer’s future revenue and stock value, but they also carry high clinical and regulatory risk.
antibody drug conjugates (ADCs) medical
"Applied to the development of antibody drug conjugates (ADCs), the technology delivers a systemically inactive prodrug"
Antibody drug conjugates (ADCs) are specialized medicines that combine a targeted antibody with a powerful drug, designed to attack specific disease cells while minimizing harm to healthy ones. This approach allows for more precise treatment, often leading to better outcomes. For investors, ADCs represent innovative therapies with the potential for significant market impact and growth in the healthcare sector.
bispecific T cell engagers medical
"including bispecific T cell engagers, bispecific ADCs and other innovative formats"
Engineered proteins that act like a two-sided connector: one side binds a T cell (an immune cell) and the other side binds a target on a diseased cell, bringing the immune cell close enough to attack and kill the target. They matter to investors because they are a distinct class of immunotherapy with clinical trial, regulatory and commercial implications—think of them as a matchmaker that directs the body's soldiers to a specific enemy, which can drive company value and partnership interest.
in vitro proof-of-concept medical
"generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform"
off-tumor toxicity medical
"face challenges associated with off-tumor toxicity caused by payload exposure in healthy tissues"
3D tumor cell spheroids medical
"demonstrated efficient and dose-dependent killing of 3D tumor cell spheroids"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

FAQ

What did VERAXA Biotech (VRXA) disclose in its June 2026 Form 6-K?
VERAXA Biotech disclosed new in vitro proof-of-concept data for its BiTAC-ADC platform. The data support tumor-restricted activation of toxic payloads and show selective killing of breast cancer cells, alongside plans to discuss partnering at BIO International Convention 2026.

What is VERAXA Biotech’s BiTAC-ADC technology platform?
BiTAC-ADC is a dual-precursor antibody drug conjugate platform designed for tumor-restricted activation of toxic payloads. It delivers an inactive prodrug and a cell-impermeable proactivator via two antibodies, each targeting a tumor-associated antigen, to enhance precision and reduce off-tumor toxicity.

What preclinical results did VERAXA Biotech report for BiTAC-ADCs?
VERAXA reported in vitro proof-of-concept data showing BiTAC-ADCs can distinguish breast cancer from healthy cells. The constructs demonstrated efficient, dose-dependent cytotoxicity against 3D tumor cell spheroids, supporting the concept of selectively delivering and activating a toxic payload in tumor cells.

How do BiTAC-ADCs aim to address off-tumor toxicity in cancer treatment?
BiTAC-ADCs are designed so individual precursors are not toxic on their own, aiming to limit payload activation to tumor cells. Only when both components are internalized into the same cancer cell is the toxic payload activated, which targets off-tumor toxicity challenges of current ADCs.

What partnering activities is VERAXA Biotech planning around its BiTAC platforms?
VERAXA plans to attend the BIO International Convention in San Diego from June 22-25, 2026. There, the company intends to discuss partnering opportunities based on its BiTAC-ADC and BiTAC-TCE platforms, which it views as differentiated product platform technologies for solid tumor indications.

How does VERAXA Biotech describe the stage of its BiTAC-ADC development?
VERAXA describes BiTAC-ADC as still early in development but now supported by in vitro proof-of-concept data. Company leadership notes the data indicate that selectively delivering and activating a toxic payload in tumor cells is working, reinforcing BiTAC-ADC as a viable platform technology.

What broader pipeline focus does VERAXA Biotech (VRXA) highlight?
VERAXA highlights a focus on next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and proprietary BiTAC formats. The company aims to rapidly advance these technologies into clinical development, building on scientific breakthroughs originating at the European Molecular Biology Laboratory.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2026

 

Commission File Number: 333-289108

 

 

 

Veraxa Biotech AG

 

 

 

Talacker 35

8001 Zurich, Switzerland

 

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

In Vitro Proof-of-Concept for BiTAC-ADC Technology Platform

 

On June 18, 2026, Veraxa Biotech AG (the “Company”) issued a press release announcing the generation of new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform and the Company's attendance at the BIO International Convention 2026 to discuss partnering opportunities.

 

A copy of the press release is attached as Exhibit 99.1 to this current report on Form 6-K and is incorporated by reference herein.

 

EXHIBIT INDEX

 

Exhibit   Description of Exhibit
99.1   Press Release dated June 18, 2026.

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VERAXA BIOTECH AG
   
Date: June 18, 2026 By: /s/ Christoph Antz
  Name: Christoph Antz
  Title: Chief Executive Officer

 

  By: /s/ Oliver Baumann
  Name: Oliver Baumann
  Title: Chairman of the Board of Directors

 

2

 

Exhibit 99.1

 

 

 

Press Release

 

 

VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel
BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026

 

● BiTAC-ADC in vitro data, along with initial data from the most advanced BiTAC-TCE program recently presented at the American Association for Cancer Research (AACR) Annual Meeting, underpin the Company’s two viable and clearly differentiated product platform technologies

 

ZURICH, SWITZERLAND – June 18, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform and its potential to enable more precise and targeted cancer therapies. VERAXA will attend the BIO International Convention in San Diego, Calif., June 22-25, 2026, to discuss partnering opportunities based on its novel BiTAC-ADC and BiTAC-TCE platforms.

 

The BiTAC™ therapeutic strategy is designed to unlock a new level of precision in cancer treatment by using two complementary precursors and enabling a tumor-restricted activation of the desired therapeutic effect. Applied to the development of antibody drug conjugates (ADCs), the technology delivers a systemically inactive prodrug and a cell-impermeable proactivator through two separate antibodies, each addressing a defined tumor-associated antigen. While the single BiTAC-ADC precursors are therefore not toxic by design, the selective internalization of both components into the same cancer cells leads to dose-dependent cytotoxicity. In in vitro studies, BiTAC-ADCs have now been shown to discriminate between breast cancer and healthy cells and have demonstrated efficient and dose-dependent killing of 3D tumor cell spheroids.

 

“Following our successful listing on NASDAQ earlier this month, the BIO International Convention presents a great opportunity and is the ideal timing to provide more details on how our BiTAC-ADC platform can be applied to the potential benefit of cancer patients,” said Heinz Schwer, Ph.D., MBA, Chief Business Officer of VERAXA. “Current ADC technologies have transformed cancer treatment but continue to face challenges associated with off-tumor toxicity caused by payload exposure in healthy tissues. BiTAC-ADCs are specifically designed to address this issue. By doing so, the platform could allow the use of very potent payloads in more settings than previously possible, with the ambition of improving both safety and targeted efficacy of next-generation ADC therapeutics.”

 

“While still early in development, the data now available for our BiTAC-ADC platform indicate that our concept of selectively delivering and activating a toxic payload in tumor cells is working,” said Christoph Erkel, Ph.D., Vice President Research & Development at VERAXA. “Following the presentation of our BiTAC-TCE strategy at the recent AACR Annual Meeting in April, these novel datasets on the BiTAC-ADC platform underpin that the company has two viable and clearly differentiated product platform technologies, which can be applied in a range of solid tumor indications by us and our potential future partners.”

 

VERAXA Biotech AG / Talacker 35 / CH-8001 Zürich
VERAXA Biotech GmbH / Im Neuenheimer Feld 584 / 69120 Heidelberg

 

 

 

 

About VERAXA Biotech AG (NASDAQ: VRXA)

 

At VERAXA, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, we are rapidly advancing our pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.

 

For regular updates about VERAXA Biotech, visit https://investors.veraxa.com/ or follow us on LinkedIn, X (formerly known as Twitter) and Bluesky.

 

Forward-looking Statements

 

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that address activities, events, or developments that VERAXA Biotech AG (the “Company”) intends, expects, plans, projects, believes, or anticipates will or may occur in the future are forward-looking statements. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this press release should be evaluated together with the many uncertainties that affect the Company’s business, particularly those identified in the risk factors section of the Company’s registration statement on Form F-4. These documents are available from the Securities and Exchange Commission, the Company website or from Company Investor Relations.

 

In addition, any information contained in this press release was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained in this press release and investors should not rely upon the information as current or accurate after the presentation date. The press release may also contain certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the Company’s website at www.veraxa.com.

 

VERAXA Biotech AG / Talacker 35 / CH-8001 Zürich
VERAXA Biotech GmbH / Im Neuenheimer Feld 584 / 69120 Heidelberg

 

2

 

 

Contact

 

VERAXA Biotech AG - Corporate  
Christoph Antz, Ph.D.
Chief Executive Officer, Co-Founder
investors@veraxa.com		  

 

For Media and Investors – U.S.

Brandon Weiner

ICR Healthcare

VERAXA@icrhealthcare.com

 

For Media and Investors – EU

Mario Brkulj

media@veraxa.com

  

 

VERAXA Biotech AG / Talacker 35 / CH-8001 Zürich
VERAXA Biotech GmbH / Im Neuenheimer Feld 584 / 69120 Heidelberg

 

3

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Press Releases